Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20124375 | 0.92 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL23453304 | 0.90 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL20124376 | 0.89 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL25853276 | 0.81 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL24981125 | 0.80 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL20124374 | 0.80 | SLC5A2 (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL24952274 | 0.79 | SLC5A2 (0.36) | SLC5A2SLC5A1 | |
| SCHEMBL25665514 | 0.77 | SLC5A2 (0.49) | SLC5A2SLC5A1 | |
| SCHEMBL20124355 | 0.77 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL23454053 | 0.76 | SLC5A1 (0.38) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023006718-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006747-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006745-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | disclosed |
| WO-2020039394-A1 | NEW DRUG COMBINATIONS | NOVARTIS AG (CH) | 2020-02-27 | — | — | WO | disclosed |